clofibrate has been researched along with Metabolic Syndrome in 6 studies
angiokapsul: contains clofibrate & insoitolnicotinate
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with clofibrate is also associated with a decrease in ANP and ANPr expression." | 5.91 | PPAR Alpha Activation by Clofibrate Alleviates Ischemia/Reperfusion Injury in Metabolic Syndrome Rats by Decreasing Cardiac Inflammation and Remodeling and by Regulating the Atrial Natriuretic Peptide Compensatory Response. ( Cano-Martínez, A; Castrejón-Téllez, V; Díaz-Díaz, E; Ibarra-Lara, L; Osorio-Yáñez, C; Pavón, N; Rubio-Ruíz, ME; Sánchez-Aguilar, M; Soria-Castro, E, 2023) |
| "Identification and treatment of the metabolic syndrome is of enormous public health importance because it is associated with a marked elevation in coronary heart disease risk and affects nearly 25% of adults in the United States." | 2.42 | Fibrates for treatment of the metabolic syndrome. ( Maki, KC, 2004) |
| "Metabolic syndrome is associated with increased cardiovascular risk." | 2.41 | [Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome]. ( Idzior-Waluś, B, 2001) |
| "Treatment with clofibrate is also associated with a decrease in ANP and ANPr expression." | 1.91 | PPAR Alpha Activation by Clofibrate Alleviates Ischemia/Reperfusion Injury in Metabolic Syndrome Rats by Decreasing Cardiac Inflammation and Remodeling and by Regulating the Atrial Natriuretic Peptide Compensatory Response. ( Cano-Martínez, A; Castrejón-Téllez, V; Díaz-Díaz, E; Ibarra-Lara, L; Osorio-Yáñez, C; Pavón, N; Rubio-Ruíz, ME; Sánchez-Aguilar, M; Soria-Castro, E, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Pirat, C | 1 |
| Farce, A | 1 |
| Lebègue, N | 1 |
| Renault, N | 1 |
| Furman, C | 1 |
| Millet, R | 1 |
| Yous, S | 1 |
| Speca, S | 1 |
| Berthelot, P | 1 |
| Desreumaux, P | 1 |
| Chavatte, P | 1 |
| Sánchez-Aguilar, M | 1 |
| Ibarra-Lara, L | 1 |
| Cano-Martínez, A | 1 |
| Soria-Castro, E | 1 |
| Castrejón-Téllez, V | 1 |
| Pavón, N | 1 |
| Osorio-Yáñez, C | 1 |
| Díaz-Díaz, E | 1 |
| Rubio-Ruíz, ME | 1 |
| Sugatani, J | 1 |
| Osabe, M | 1 |
| Wada, T | 1 |
| Yamakawa, K | 1 |
| Yamazaki, Y | 1 |
| Takahashi, T | 1 |
| Ikari, A | 1 |
| Miwa, M | 1 |
| Maki, KC | 1 |
| Iwasaki, Y | 1 |
| Takayasu, S | 1 |
| Nishiyama, M | 1 |
| Tsugita, M | 1 |
| Taguchi, T | 1 |
| Asai, M | 1 |
| Yoshida, M | 1 |
| Kambayashi, M | 1 |
| Hashimoto, K | 1 |
| Idzior-Waluś, B | 1 |
3 reviews available for clofibrate and Metabolic Syndrome
| Article | Year |
|---|---|
Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators.
Topics: Animals; Humans; Ligands; Metabolic Syndrome; Models, Molecular; Molecular Targeted Therapy; Peroxis | 2012 |
Fibrates for treatment of the metabolic syndrome.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Clofibrate; Fenofibrate; Gemfibrozil; Humans; Hyp | 2004 |
[Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome].
Topics: Cardiovascular Diseases; Clofibrate; Fenofibrate; Hemostasis; Humans; Hyperinsulinism; Hyperlipidemi | 2001 |
3 other studies available for clofibrate and Metabolic Syndrome